Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.63 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30536136 | 1.00 | BRD4 (0.63) | BRD4NT5C2NT5ELMNACYP1A2 | |
| SCHEMBL5694112 | 0.83 | NPC1 (0.49) | LMNATSHRMEN1NPC1TP53 | |
| SCHEMBL38666421 | 0.82 | BRD4 (0.66) | BRD4NT5C2NT5ELMNACYP1A2 | |
| SCHEMBL5694094 | 0.82 | XDH (0.51) | NPC1TP53RAB9A | |
| SCHEMBL6933552 | 0.81 | ALPL (0.52) | LMNATSHRNPC1TP53MAPT | |
| SCHEMBL38663949 | 0.80 | BRD4 (0.58) | BRD4NT5C2NT5ECYP1A2TSHR | |
| SCHEMBL28828155 | 0.78 | BRD4 (0.59) | BRD4NT5C2NT5ECYP1A2TSHR | |
| SCHEMBL23124 | 0.78 | BRD4 (1.00) | BRD4NT5C2NT5ENPC1RAB9A | |
| SCHEMBL29514799 | 0.78 | BRD4 (1.00) | BRD4NT5C2NT5ENPC1RAB9A | |
| SCHEMBL6463477 | 0.77 | BRD4 (0.92) | BRD4NT5C2NT5ECREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862868-B1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO CO LTD (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-9738681-B2 | Intermediate for production of nucleoside analog and method for producing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-10 | — | — | US | disclosed |
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2862868-A1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-6573045-B1 | Reporter molecule and RNA target molecule, both carrying a fluorescent or chromogenic group, placed in close proximity to each other; addition of test compound inhibits their binding and increases fluorescence; drug screening | RIBOTARGETS, LTD. (GB) | 2003-06-03 | — | — | US | disclosed |
| EP-1144681-A3 | METHODS AND KITS FOR DISCOVERY OF RNA-BINDING COMPOUNDS | RiboTargets Limited (GB) | 2001-11-28 | — | — | EP | disclosed |
| EP-1144681-A2 | METHODS AND KITS FOR DISCOVERY OF RNA-BINDING COMPOUNDS | RiboTargets Limited (GB) | 2001-10-17 | — | — | EP | disclosed |
| WO-1999064625-A2 | METHODS AND KITS FOR DISCOVERY OF RNA-BINDING COMPOUNDS | RIBOTARGETS LIMITED (GB) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | BRD4 3169/4885NT5C2 185/4885NT5E 183/4885 |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | BRD4 3169/4885NT5C2 185/4885NT5E 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.